Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study

详细信息    查看全文

• 作者：Naila Makhani ; MD ; MPH^a ; ^b ; ^{naila.makhani@yale.edu" class="auth_mail" title="E-mail the corresponding author} ; Teri Schreiner ; MD ; MPH^c ; ^d
• 关键词：multiple sclerosis ; oral therapy ; dimethyl fumarate ; Expanded Disability Status Scale
• 刊名：Pediatric Neurology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：57
• 期：Complete
• 页码：101-104
• 全文大小：251 K

文摘

First-line injectable therapies for multiple sclerosis in children may be ineffective or not well-tolerated. There is therefore an urgent need to explore oral medications for pediatric multiple sclerosis. We review our dual-center experience with oral dimethyl fumarate.

Methods

This study was a retrospective review of children 18 years of age or less with multiple sclerosis treated with dimethyl fumarate at Yale University and the University of Colorado. Clinical, demographic, and magnetic resonance imaging parameters were analyzed.

Results

We identified 13 children treated with oral dimethyl fumarate for a median of 15.0 months (range, 1 to 25). Dimethyl fumarate was utilized as first-line therapy in five children (38%). Ten children (77%) tolerated dose escalation to the usual adult dose of 240 mg twice daily. Nine children had ≥12 months of follow-up on treatment. Eight of nine (89%) displayed stabilized or reduced relapse rates and disability scores on treatment. Nine children underwent brain magnetic resonance imaging performed after 12 or more months of therapy. New T2 lesions were observed in three children (33%), one of whom had been nonadherent to treatment. Common side effects included facial flushing (8/13, 62%), gastrointestinal discomfort (7/13, 54%), rash (3/13, 23%), and malaise (2/13, 15%). Three children (23%) discontinued treatment because of side effects. No patients displayed laboratory abnormalities including lymphopenia or abnormal liver transaminases. There were no reported infections.

Conclusions

Oral dimethyl fumarate appears to be safe and generally well tolerated in children with multiple sclerosis. Formal clinical trials to evaluate efficacy are ongoing.